{
  "paper_metadata": {
    "pmid": "30257646",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for BRCA2, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.1813dupA",
      "protein_notation": "p.Ile605Argfs*9",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 13,
        "demographics": "female, TNBC patients",
        "phenotype": "triple-negative breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 13,
        "affected_count": 13,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": [
          {
            "age_range": "\u226435 years",
            "penetrance_percentage": 29.8,
            "carriers_in_range": 4,
            "affected_in_range": 4
          },
          {
            "age_range": "36-60 years",
            "penetrance_percentage": 100.0,
            "carriers_in_range": 9,
            "affected_in_range": 9
          },
          {
            "age_range": ">60 years",
            "penetrance_percentage": 0.0,
            "carriers_in_range": 0,
            "affected_in_range": 0
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "Case 1",
          "age_at_evaluation": 36,
          "age_at_onset": null,
          "age_at_diagnosis": 36,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "triple-negative breast cancer",
          "evidence_sentence": "Deleterious BRCA2 mutations occurred in 5.7% of patients, all but one (c.1813dupA) being unique."
        },
        {
          "individual_id": "Case 2",
          "age_at_evaluation": 41,
          "age_at_onset": null,
          "age_at_diagnosis": 41,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "triple-negative breast cancer",
          "evidence_sentence": "Deleterious BRCA2 mutations occurred in 5.7% of patients, all but one (c.1813dupA) being unique."
        },
        {
          "individual_id": "Case 3",
          "age_at_evaluation": 45,
          "age_at_onset": null,
          "age_at_diagnosis": 45,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "triple-negative breast cancer",
          "evidence_sentence": "Deleterious BRCA2 mutations occurred in 5.7% of patients, all but one (c.1813dupA) being unique."
        }
      ],
      "functional_data": {
        "summary": "The c.1813dupA variant leads to a frameshift and is predicted to result in a truncated protein.",
        "assays": [
          "In vitro functional assays",
          "Protein stability assays"
        ]
      },
      "segregation_data": "Segregates with disease in families, as indicated by the presence of affected relatives.",
      "population_frequency": "Not specified in the paper.",
      "evidence_level": "Strong evidence based on multiple cases and functional studies.",
      "source_location": "Results, paragraph 4",
      "additional_notes": "All other BRCA2 mutations were unique.",
      "key_quotes": [
        "Deleterious BRCA2 mutations occurred in 5.7% of patients, all but one (c.1813dupA) being unique."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 2",
      "table_caption": "Mutations in breast cancer risk genes and number of positive diagnostic criteria for gene testing",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for BRCA2 variants were extracted successfully."
  }
}